Company overview
Neurolentech develops patient-derived neuronal cell models from iPSCs for drug discovery and diagnostics targeting neurodevelopmental disorders like autism, epilepsy, and intellectual disability. Their precision medicine platform combines disorder-specific models with molecular and physiological assays to identify druggable targets and validate therapeutics. They partner with biopharma companies to advance treatments for these high-unmet-need conditions.
Neurolentech is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include neurolentech, ndd drug discovery, patient-derived models, epilepsy models, autism research, ipsc neurons.
Structured facts
- Website
- https://neurolentech.com
- Markets served
- United States & Americas
- Keywords
- neurolentech, ndd drug discovery, patient-derived models, epilepsy models, autism research, ipsc neurons
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What capabilities does Neurolentech offer for neurodevelopmental disorder drug discovery?
- Neurolentech provides a platform with proprietary patient-derived iPSC neuronal cell models and functional assays for epilepsy, autism, and related NDDs to identify molecular mechanisms and validate therapeutics.
- What types of cell models and assays are available?
- They offer human iPSC-derived neuronal models from patients across the NDD spectrum, with assays interrogating molecular and cellular disease mechanisms.
- Who are Neurolentech's typical partners and geographies?
- Neurolentech partners with biopharma like Kaerus Bioscience and o2h technology; as an IST Austria spin-out based in Austria, they serve global pharma clients focused on NDD research.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
